secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001818382-24-000146
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care
--------------------------------------------------------------------------------

- ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.
- ATEV also demonstrated significantly longer hemodialysis duration over 12 months (p=0.0162).
- Company plans to discuss potential market authorization pathway with FDA soon.
- More adverse events were reported in the ATEV arm compared to the fistula arm.
- Over 800,000 Americans have end-stage renal disease; ATEV is an off-the-shelf bioengineered vessel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/0001818382-24-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/huma-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer